Comparing the current results to its competitors, Maravai Lifesciences Holdings Inc reported Revenue increase in the 2 quarter 2026 by 8.53 % year on year. The revenue growth was below Maravai Lifesciences Holdings Inc 's competitors' average revenue growth of 9.64 %, achieved in the same quarter.
Maravai Lifesciences Holdings Inc , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 9.2 %
Maravai Lifesciences Holdings Inc 's Comment on Competition and Industry Peers
TriLink operates in multiple segments and faces competition from various companies. Its competitors include chemistry companies producing monomers and amidites, custom oligonucleotide manufacturers, mRNA-focused biotechnology firms, and contract development and manufacturing organizations (CDMOs). In the mRNA capping segment, competitors consist of providers of enzymatic capping solutions and customers' in-house processes. For mRNA and GMP services, competitors include other mRNA manufacturers and CDMOs. In oligonucleotide synthesis inputs, competition comes from large distributor-manufacturers, while in specialty enzymes, established life science enzyme providers are competitors. Cygnus competes with providers of impurity detection kits and companies offering custom assay development, including certain contract research organizations (CROs) and CDMOs.
April 23, 2025
Maravai LifeSciences Holdings, Inc. Faces Legal Troubles Amid Lackluster Financial PerformanceOn April 23, 2025, Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) found itself embroiled in a legal controversy as The Gross Law Firm issued a notice to its shareholders regarding potential securities law violations. This announcement invites shareholders to discuss their rights in light of the ongoing legal proceedings set to commence before May 5, 2025.The legal challenges facing Maravai come at a time when the company is also grappling with disappointing financial performance. In its fourth quarter of 2024, Maravai reported no growth in revenue compared to the previous year, with a stagnation rate of 0% year...
April 9, 2025
In recent developments, Bronstein, Gewirtz and Grossman LLC has announced its intention to lead a class action lawsuit for investors of Maravai LifeSciences Holdings, Inc. who have incurred substantial losses. This announcement arrives during a pivotal moment for the company, which has displayed a complex financial performance in its latest quarterly report.Maravai LifeSciences reported a net cash outflow in the fourth quarter of 2024; however, contextualizing this information is crucial. Despite the negative cash flow, Maravai managed to achieve the highest net cash flow margin within the biotechnology industry for the same period. This noteworthy accomplishment positions the company favorably when compared...
April 9, 2025
Maravai LifeSciences Holdings, Inc.: A Crucial Moment for Investors as Class Action Lawsuits Progress In recent weeks, investors in Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) have faced significant turmoil as a class action lawsuit has been initiated against the company and its executives. As outlined in announcements from respected law firms, including Bronstein, Gewirtz and Grossman LLC, Levi and Korsinsky LLP, and Rosen Law Firm, shareholders who have experienced substantial financial losses now have an opportunity to take decisive action in pursuing their rights. Understanding the Class Action Lawsuit The class action lawsuit comes in the wake of considerable stock value depreciation for Maravai ...
April 7, 2025
The landscape of pharmaceutical investments can be as unpredictable as the market itself. Nowhere is this more evident than with Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI), which has recently found itself embroiled in a class action lawsuit that could significantly affect its stock performance. Levi and Korsinsky LLP, a law firm known for advocating for investors, has alerted shareholders of the impending legal proceedings tied to recent allegations concerning potential violations of securities laws. As April unfolds, the question remains: what does this mean for the stakeholders involved and the pharmaceutical industry at large Recent data paints a troubling picture for Maravai LifeSciences. Over th...
April 4, 2025
: This article explores the unfolding class action lawsuit against Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI), focusing on the securities litigation spearheaded by prominent law firms Levi and Korsinsky, LLP, and Rosen Law Firm. It examines the implications for investors, the legal proceedings, and the potential impacts on the pharmaceutical industry. Maravai LifeSciences Holdings, Inc. a prominent player in the pharmaceutical and life sciences industry, finds itself in the midst of a significant legal battle. This case highlights the importance of corporate transparency and investor rights within the context of securities law. Two major law firms, Levi and Korsinsky, LLP, and Rosen Law Firm, are ...
March 27, 2025
: Maravai Lifesciences Holdings, Inc. (NASDAQ: MRVI) is currently facing a securities class action lawsuit that invites affected investors to participate. This article synthesizes critical information from recent legal announcements to inform stakeholders of the current developments and deadlines associated with the case.Maravai Lifesciences Holdings, Inc. a company engaged in life science products and services, finds itself at the center of legal scrutiny due to allegations of securities fraud. Two leading law firms, Rosen Law Firm and Robbins Geller Rudman and Dowd LLP, are representing investors in a class action lawsuit stemming from alleged violations of the Securities Exchange Act of 1934. This article...
April 18, 2024
TriLink BioTechnologies Expands mRNA Drug Production Capabilities with New San Diego FacilityTriLink BioTechnologies, a global life sciences company operating under Maravai LifeSciences, has announced the opening ceremony of its state-of-the-art mRNA production facility in San Diego. This new facility, covering an area of 32,000 square meters, has been specifically designed to support companies in the development of mRNA-based drugs in accordance with current Good Manufacturing Practice (cGMP) guidelines. This article aims to provide an in-depth analysis of TriLink BioTechnologies expansion and its potential impact on the pharmaceutical sciences field.1. The Role of mRNA in Advancing Drug Development:mRNA-b...
Publicly Traded Peers of Maravai Lifesciences Holdings Inc
Agilent Technologies inc Share Performance
+6.72%
This Quarter
Agilent Technologies inc
Profile
Agilent Technologies Inc. operates a business model centered on delivering innovative measurement solutions across industries like life sciences, diagnostics, and chemical analysis. Their revenue primarily comes from sales of instruments, software, and consumables, supplemented by support services. The company emphasizes strong partnerships and collaborations to enhance their market presence and influence.
AnaptysBio is a biotechnology company that operates on a partnership-driven business model. They collaborate with pharmaceutical companies to develop and commercialize novel antibody therapeutics using their proprietary antibody discovery technology. By leveraging their expertise in antibody engineering and discovery, AnaptysBio aims to create innovative treatments for a wide range of diseases, including inflammation, immuno-oncology, and rare diseases.
Bio-Rad Laboratories Inc operates as a global leader in life sciences and clinical diagnostics by focusing on the development, manufacturing, and distribution of a diverse array of products and solutions. Their business model emphasizes innovation, providing advanced tools and technologies that empower scientists and healthcare professionals to effectively analyze biological materials. By delivering high-quality solutions, Bio-Rad aims to facilitate scientific breakthroughs and enhance patient care in various healthcare settings.
Illumina Inc is a leading company in the genomics sector, focusing on next-generation sequencing technologies that enhance genetic analysis. Their business model encompasses a diverse range of products, including sequencing platforms, reagents, and bioinformatics solutions, which together facilitate comprehensive genomic studies for researchers. By integrating these tools, Illumina supports advancements in fields such as oncology, drug discovery, and personalized healthcare, positioning itself at the forefront of genomic innovation.
Sources:
Maravai Lifesciences Holdings Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Maravai Lifesciences Holdings Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
